A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: A preliminary report
作者： Paul Mommen , Jean Paul Sculier , Gérard Dabouis , Claude Finet , Gérard Bureau
DOI: 10.5555/URI:PII:009377549090067D
关键词: Nephrotoxicity 、 Etoposide 、 Medicine 、 Randomized controlled trial 、 Lung cancer 、 Gastroenterology 、 Nausea 、 Internal medicine 、 Oncology 、 Vomiting 、 Carboplatin 、 Cisplatin
摘要: A randomized study with cisplatin (120 mg/m*) or carboplatin (325 mg/m*j plus etoposide (100 ma/m’, days 1 to 3) in 162 evaluable patients advanced non-small cell lung cancer (NSCLC) compared response and survival after treatment. No statistically significant difference rates was detected: median 25 weeks for receiving 24 those carboplatin. The objective rate 25% 20% etoposide. Granulocytopenia, diarrhea, nephrotoxicity were significantly more frequent than Severe nausea and/or vomiting occurred during 59 of 77 courses (77%) 48 75 (64%) (P = .13). Unlike etoposide, administered on an outpatient basis. At the dose used present study, as effective but less toxic NSCLC could be given easily. Q 1990 by W.S. Saunders Company.
ulb.ac.be
sci-hub.st 参考文章(15)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
J Klastersky, J P Sculier, G Bureau, P Libert, P Ravez, G Vandermoten, J Thiriaux, J Lecomte, R Cordier, G Dabouis, Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. Journal of Clinical Oncology. ,vol. 7, pp. 1087- 1092 ,(1989) , 10.1200/JCO.1989.7.8.1087
M Rozencweig, C Nicaise, M Beer, N Crespeigne, M Van Rijmenant, L Lenaz, Y Kenis, Phase I study of carboplatin given on a five-day intravenous schedule. Journal of Clinical Oncology. ,vol. 1, pp. 621- 626 ,(1983) , 10.1200/JCO.1983.1.10.621
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Elias Tueni, Jean-Paul Sculier, Jean Klastersky, Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. European Journal of Cancer and Clinical Oncology. ,vol. 24, pp. 963- 967 ,(1988) , 10.1016/0277-5379(88)90143-5
Jean-Paul Sculier, Jean Klastersky, Progress in chemotherapy of non-small cell lung cancer European Journal of Cancer and Clinical Oncology. ,vol. 20, pp. 1329- 1333 ,(1984) , 10.1016/0277-5379(84)90049-X
A. H. Calvert, S. J. Harland, D. R. Newell, Z. H. Siddik, A. C. Jones, T. J. McElwain, S. Raju, E. Wiltshaw, I. E. Smith, J. M. Baker, M. J. Peckham, K. R. Harrap, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II Cancer Chemotherapy and Pharmacology. ,vol. 9, pp. 140- 147 ,(1982) , 10.1007/BF00257742
Emile Longeval, Jean Klastersky, Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) Cancer. ,vol. 50, pp. 2751- 2756 ,(1982) , 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
RICHARD J. GRALLA, Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules Annals of Internal Medicine. ,vol. 95, pp. 414- 420 ,(1981) , 10.7326/0003-4819-95-4-414